Zhengye Biotechnology Holding Limited (ZYBT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 214 | 260 | 212 | 186 | 116 | 80 | - |
| Operating profit | CNY m | -68 | -62 | ||||||
| Net profit | CNY m | - | 39 | 47 | 31 | 11 | -70 | -71 | - |
| EPS reported | CNY | -1.40 | -1.49 | ||||||
| Operating cashflow per share | CNY | 0.28 | 0.85 | ||||||
| Capex per share | CNY | 0.27 | 0.02 | ||||||
| FCF per share | CNY | 0.01 | 0.82 | ||||||
| Free cash flow | CNY m | 1 | 39 | ||||||
| Net debt | CNY m | 23 | 23 | ||||||
| Book value equity | CNY m | 250 | 250 | ||||||
| Book value per share | CNY | 5.28 | 5.27 | ||||||
| Number of shares | m | 47.35 | 47.39 | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.52 | 1.52 | ||||||
| P/S LTM | x | 3.27 | 4.76 | ||||||
| P/FCF LTM | x | 541.63 | 9.74 | ||||||
| EV/EBITDA LTM | x | -9.54 | -9.79 | ||||||
| EV/Sales LTM | x | 3.48 | 7.88 | ||||||
| Earnings Yield LTM | % | -18.33% | -11.77% | ||||||
| FCF Yield | % | +0.18% | +10.26% | ||||||
| Quality | |||||||||
| ROE | % | -27.93% | -26.78% | ||||||
| ROIC | % | -17.87% | -16.15% | ||||||
| Operating margin | % | -58.66% | -77.04% | ||||||
| Gross margin | % | +20.51% | +8.30% | ||||||
| FCF/Sales | % | +0.60% | +48.82% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -37.56% | -57.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -94.70% | +194.44% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.01 | 0.52 | ||||||
| Net Debt/EBITDA | x | -0.58 | -0.60 | ||||||
| EBIT/Net interest | x | -20.07 | -38.13 | ||||||
| Net debt/market cap | % | +19.61% | +12.32% | ||||||
| Net debt/Equity | x | 0.09 | 0.09 | ||||||
| Gross debt/equity | x | 0.30 | 0.30 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zhengye Biotechnology Holding Limited (ZYBT)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free